Sacituzumab Govitecan

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.

**Synonyms:** - IMMU 132 - IMMU-132 - IMMU132 - RS7 SN38 - RS7-SN38 - RS7SN38 - SACITUZUMAB GOVITECAN - Sacituzumab Govitecan-hziy - Sacituzumab govitecan - Trodelvy - hRS7-SN38 Antibody Drug Conjugate